Append Medical Selected to Present First-Of-Its-Kind, No-Implant Stroke Risk Reduction Device at ICI Meeting 2019

Append Medical Selected to Present First-Of-Its-Kind, No-Implant Stroke Risk Reduction Device at ICI Meeting 2019

Append Medical’s Novel Approach to Left Atrial Appendage (LAA) Closure to be Featured at International Conference for Innovations in Cardiovascular Interventions

OR YEHUDA, Israel –December 5, 2019 — Append Medical, developer of a novel LAA closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition.

Append Medical will also present in the Digital Presentations: Complex Coronary and Valvular Interventions program during the meeting.
Originally conceived by Professor Leonid Sternik, MD, Director of the Department of Cardiac Surgery at Sheba Medical Center, the Append Medical “Appligator™” device is designed to reduce stroke risk in AF patients by completely closing the LAA to prevent blood clot leakage. Its design is intended to minimize device-related thromboembolism risk by leaving only a suture – and no metal – at the closure site.

The LAA closure market is the second-fastest growing segment of the medical device market, estimated to reach $958 million by 2025, according to Energias Market Research.

The company operates as part of MEDX Xelerator in Israel. MEDX Xelerator’s partners include MEDX Ventures, Boston Scientific Inc., Intellectual Ventures and Sheba Medical Center.
For more information on the 2019 ICI Meeting, and the Global Innovation Award Competition, please visit


About Append Medical
Founded in 2017, Append Medical is the developer of a patented No-Implant Left Atrial Appendage (LAA) closure solution. The Appligator™ is designed to achieve full closure of the LAA to reduce stroke risk in patients with non-valvular atrial fibrillation. Append Medical is a privately held company operating as part of MEDX Xelerator in Israel. Its major shareholders are MEDX Ventures, Boston Scientific Inc, Intellectual Ventures and the company’s founders.

Media Contact:
Finn Partners for Append Medical
Nicole Grubner
[email protected]



This website uses cookies

We use cookies to enhance your experience on our site. Visit our Privacy Policy and Terms and Conditions of Use to learn more. By using our site, you agree to our use of cookies.

Agree | Learn More
Subscribe to Newsletter